
|Videos|December 21, 2017
Dr. Hamilton on FDA Approval of Adjuvant Pertuzumab Regimen in HER2+ Early Breast Cancer
Author(s)Erika P. Hamilton, MD
Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of pertuzumab (Perjeta) for use in combination with trastuzumab (Herceptin) and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer.
Advertisement
Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of pertuzumab (Perjeta) for use in combination with trastuzumab (Herceptin) and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5



































